GlassScriptPhysician profile
Margaret Grossman
NPI 1538389101
$11,090.73
in general payments reported to CMS, 2019-2025
54 companies · $1,433 in 2025
The $1,433 reported for 2025 was more than what 94% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,089 · 2020: $1,508 · 2021: $1,826 · 2022: $1,650 · 2023: $1,858 · 2024: $1,728 · 2025: $1,433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,944 · Education: $73.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,944.42 |
| Education | $73.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,003.54 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $858.58 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $726.43 | 2019-2025 | Jardiance, Synjardy, Spiriva Respimat |
| Bayer Healthcare Pharmaceuticals INC. | $723.71 | 2021-2025 | |
| Novo Nordisk INC | $658.39 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $572.33 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $521.66 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Sanofi-Aventis U.S. LLC | $447.48 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $429.86 | 2019-2024 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $427.07 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $426.53 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $335.07 | 2019-2022 | |
| Corcept Therapeutics | $256.07 | 2020-2025 | Korlym |
| Abbott Laboratories | $252.34 | 2021-2025 | Freestyle Libre 3 |
| Pfizer INC. | $192.98 | 2019-2024 |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $179.79 | 2020-2025 | Veozah |
| Arbor Pharmaceuticals, INC. | $153.60 | 2019-2021 | |
| Esperion Therapeutics, INC. | $148.22 | 2020-2024 | Nexletol |
| Abiomed | $127.21 | 2024 | Impella |
| Xeris Pharmaceuticals, INC. | $122.81 | 2022 | |
| Amgen INC. | $117.94 | 2019-2025 | Otezla, Repatha |
| Dexcom, INC. | $115.11 | 2021-2024 | Dexcom G6 Transmitter |
| Abbvie INC. | $113.21 | 2021-2024 | |
| Vanda Pharmaceuticals INC. | $90.12 | 2022-2023 | Hetlioz |
| Insulet Corporation | $68.68 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $67.84 | 2022-2023 | Rexulti |
| Welch Allyn | $64.38 | 2021 | |
| Baxter Healthcare | $64.38 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $63.32 | 2021-2025 | Zoryve |
| Eisai INC. | $63.26 | 2020-2021 | |
| Ardelyx, INC. | $60.18 | 2025 | Ibsrela |
| Sumitomo Pharma America, INC. | $48.69 | 2024-2025 | Gemtesa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48.11 | 2022 | |
| Corvista Health, INC. | $47.01 | 2025 | Corvista System |
| Genentech USA, INC. | $46.54 | 2020-2021 | |
| Optinose US, INC. | $40.24 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $37.97 | 2023-2024 | Inpefa |
| Exact Sciences Corporation | $36.72 | 2024-2025 | Cologuard Collection Kit |
| Hikma Pharmaceuticals USA | $32.87 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $31.60 | 2021 | |
| Allergan, INC. | $27.25 | 2019-2020 | |
| Daiichi Sankyo INC. | $26.73 | 2023 | Injectafer |
| Amarin Pharma, INC. | $26.48 | 2019-2021 | |
| Novavax INC | $24.10 | 2023 | Novavax Covid-19 Vaccine, Adjuvanted |
| Seqirus USA INC | $21.66 | 2024 | Flucelvax |
| Indivior INC. | $21.05 | 2025 | Sublocade |
| Scpharmaceuticals INC. | $19.55 | 2025 | |
| Verona Pharma, INC. | $17.63 | 2025 | Ohtuvayre |
| Edwards Lifesciences Corporation | $16.58 | 2021 | |
| Shire North American Group INC | $15.76 | 2019 | |
| Philips North America LLC | $14.81 | 2019 | |
| Opko Pharmaceuticals, LLC | $14.69 | 2019 | |
| Mylan Specialty L.P. | $11.30 | 2019 | |
| Horizon Therapeutics Plc | $11.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Grossman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.